Navigation Links
Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
Date:2/28/2008

Robert G. Johnson, Jr. Resigns as President and Chief Executive Officer

Development Portfolio Focused on Near-Term Commercial Opportunities

HAYWARD, Calif., Feb. 28 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) today announced that Robert G. Johnson, Jr., M.D., Ph.D., has resigned as President and Chief Executive Officer and a member of Kosan's Board of Directors. Helen S. Kim, who joined Kosan in January 2008 as Senior Vice President and Chief Business Officer, has been appointed President of Kosan.

"Under Robert's leadership, Kosan made the successful transition from a research-oriented organization to a product development-focused company, and he has made many significant contributions to Kosan over the last eight years," said Peter Davis, Ph.D., Chairman of Kosan's Board of Directors. "Robert assumed the chief executive officer role during a period of transition and executed his responsibilities skillfully and energetically. He helped Kosan to manage a period of significant change to emerge as a better-positioned company and to recruit the senior management team that will help lead the company into its next phase. His commitment to Kosan has been intense, and his positive influence has been felt throughout the company. We express our sincerest thanks to Robert and wish him well in his new pursuits." Dr. Davis also noted: "Our new President, Helen Kim, has broad experience in product development and commercialization, as well as business and corporate development. These talents plus her demonstrated leadership will strengthen Kosan's ability to advance key product candidates toward the market."

Kosan also announced that the company has reprioritized its development portfolio. The compa
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
2. Kosan Announces February 28, 2008 Conference Call and Webcast
3. Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
4. Kosan Announces Third Quarter 2007 Financial Results
5. Kosan to Reacquire Epothilone Program From Roche
6. Kosan Biosciences to Host Research & Development Day on October 31, 2007
7. Kosan Biosciences to Present at the Biotechnology Industry Organization Investor Forum
8. Kosan Biosciences to Present at the 2007 UBS Global Life Sciences Conference
9. Kosan Biosciences to Present at the Bear Stearns 20th Annual Healthcare Conference
10. Wyeth Announces Executive Change in Finance Organization
11. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... and Annapolis Junction, MD (PRWEB) July 28, 2014 ... research leader in personalized medicine, will be exhibiting data ... at this year’s International Spine Intervention Society’s ... place July 30th-August 3rd, at the Hyatt Regency, in ... to enhance the knowledge and clinical competence of physicians ...
(Date:7/28/2014)... TORONTO , July 28, 2014 /PRNewswire/ -   ... latest group of companies to join its growing portfolio ... hallmarks of Toronto,s JOLT accelerator, ... startups on the roster. Since its ... that have successfully raised  $7.5M of financing. Now at ...
(Date:7/28/2014)... 28, 2014  David Hardison, Ph.D., vice president ... , has been elected chairman of the board ... non-profit working to establish common protocols around the ... relates to electronic health records. ... collaborating with organizations across the research and health ...
(Date:7/28/2014)...   Propeller Health , the FDA-cleared digital health ... Brad Towle as Senior Vice President, Business ... the company,s sales growth, customer acquisition and program expansion. ... his past role in the development of accountable care ... pivotal time in the industry," said David Van ...
Breaking Biology Technology:Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 3ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2
... Hefty has seen blue-ribbon government panels come and go ... thick file of reports spanning 20 years of commissions, ... thoughtful research papers is only useful if it leads ... Hefty, who retired last year from Blue-Cross/Blue Shield United ...
... Role in Community...promotes entertainment everywhere on any device ... approval for the sale of the companys desktop products ... (SPD) The transaction is now complete and Sony Pictures ... it will keep the companys employee base in Madison ...
... alternative energy , ,Madison, WI - WE Energies ... two developers that will build three wind farms increasing ... by 400%. , ,Under the agreement, the two developers, ... LLC, based in Chicago, will provide their entire energy ...
Cached Biology Technology:Governors Growth Council hopes to go light on paperwork and heavy on ideas 2Governors Growth Council hopes to go light on paperwork and heavy on ideas 3Sony Completes Acquisition of Sonic Foundry 2Sony Completes Acquisition of Sonic Foundry 3WE Energies Is Not Letting Wind Power Blow Away 2
(Date:7/28/2014)... and other forms of dementia, but the research community ... of Washington bioengineers have a designed a peptide structure ... normal proteins into a state that,s linked to widespread ... diabetes and Lou Gehrig,s disease. The synthetic molecule blocks ... into an abnormally folded form by targeting a toxic ...
(Date:7/28/2014)... research has identified areas of the Earth that are ... change. , Europe is particularly vulnerable, as it has ... per cent, of any continent in ,refugia, areas ... environmental conditions remain relatively constant during times of great ... are mostly in Scandinavia and Scotland. , The ...
(Date:7/28/2014)... St. Jude Children,s Research Hospital study found that 73 ... doubled their risk of developing metabolic syndrome and related ... The results appear in the current issue of the ... the 1,598 adult survivors of childhood cancer in the ... risk factors like high blood pressure, abdominal obesity, elevated ...
Breaking Biology News(10 mins):New protein structure could help treat Alzheimer's, related diseases 2New protein structure could help treat Alzheimer's, related diseases 3Study finds Europe's habitat and wildlife is vulnerable to climate change 2Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 2Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 3
... comparing the immune responses of both, young and old ... of macrophages, one of the major cell populations involved ... aged mice. This decline in the number of fighters ... be responsible for the age-associated increase in susceptibility to ...
... 2010 Burnham Institute for Medical Research (Burnham) announced ... million to support and further expand and accelerate the ... been renamed the Sanford-Burnham Medical Research Institute. This is ... 2007, he directed $20 million through Sanford Health to ...
... FAIRFAX, Va.Nearly 5,300 physicians, scientists and allied health ... Interventional Radiology,s 35th Annual Scientific Meeting March 13󈝾 ... are scheduled for 9󈝶:30 a.m. on both Monday, ... Annual Scientific Meeting offers ...
Cached Biology News:Rejuvenating the old immune system 2T. Denny Sanford donates $50 million to Burnham Institute for Medical Research 2Press registration open for Society of Interventional Radiology’s 35th Annual Scientific Meeting 2
GeneRacer is an advanced RACE (rapid amplification of cDNA ends) technique that improves the efficiency of amplifying full-length 5' and 3' cDNA ends. With the GeneRacer Kit you can:...
One-step, microplate or cuvet, colorimetric, detection range 0.04% to 4%. Procedure: 30 min....
... 26] to Presenilin 2 Alzheimer's disease ... the disease carry mutations in the presenilin ... protein (APP). These disease-linked mutations result in ... amyloid-beta (main component of amyloid deposits found ...
One-step, microplate or cuvet, colorimetric, linear detection range 0.7 mg/dL to 35 mg/dL. Procedure: 5 min....
Biology Products: